| Comparing the effectiveness of buccal infiltration of different volumes of Articaine for extraction of mandibular posterior teeth- A randomized clinical trial. |
Ongoing |
ARTICAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE |
4 |
6074514624 |
Dental Clinic-collage of Dentistry-Qassim Unviersity (Al-Qassim) |
| The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency |
Ongoing |
INZ-701 |
3 |
INZ701-105 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
Ongoing |
Efgartigimod IV |
3 |
ARGX-113-2308 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice |
Ongoing |
Anifrolumab |
4 |
TMP-0010230 |
Aseer Central Hospital (Abha), International Medical Center (Jeddah),King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. |
Terminated |
Macitentan (ACT-064992, Opsumit ®) |
3 |
67896062CTP3001 |
King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial. |
Ongoing |
Articaine |
3 |
607-43-7809 |
Qassim Regional Dental Center,The One Clinic (Buraydah) |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross over Study of Oral Deucrictibant Soft Capsule for On Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema |
Ongoing |
Deucrictibant |
3 |
PHA022121-C306 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) |
Ongoing |
Nipocalimab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) |
Ongoing |
Tirzepatide |
4 |
I8F-MC-GPIY |
Al Moosa Specialized Hospital (al ahsa), King Faisal Specialist Hospital and Research Center (Riyadh), Saudi Airlines Medical Service Center (Jeddah), King Fahad Medical City (Riyadh), Dallah Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Madinah) |
| CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
Ongoing |
Camizestrant (AZD9833) |
3 |
8535C00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
